presentation

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…

2 weeks ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered…

2 weeks ago

The Shaw Prize Award Presentation Ceremony 2025: Continuing 22 Years of Legacy in Science and Innovation

HONG KONG, Oct. 21, 2025 /PRNewswire/ -- The Shaw Prize presented its awards to four 2025 Shaw Laureates today at…

2 weeks ago

Netrack Engages Industry Leaders at BICSI Chennai with Future-oriented IT-solutions

Netrack’s participation in the BICSI event in Chennai on December 21st 2024, marked the year with productivity and success. As…

3 weeks ago

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

3 weeks ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…

1 month ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

1 month ago

Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

1 month ago

Minelab Premieres the VANQUISH 60 Series: Simple Yet Powerful

LONDON, Sept. 17, 2025 /PRNewswire/ -- Minelab officially unveiled the new VANQUISH 60 Series on 11 September 2025 at a…

2 months ago

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…

3 months ago